Streetbeat News

Regulatory

CDIO

Cardio Diagnostics Holdings has been granted a patent in India, numbered 484488, for a kit that determines the methylation status of a CpG dinucleotide and a genotype of a single nucleotide polymorphism. The company now holds patents in multiple regions globally, including the United States, Europe, Australia, China, and Hong Kong, with additional patents pending worldwide.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:36 pm

YTEN

Yield10 Bioscience has submitted a request to the USDA-APHIS for a regulatory status review of its genetically designed Camelina plants, which are engineered to produce EPA and DHA, key components of Omega-3 oil. The review is a step towards commercializing the product, which could have implications for the agriculture and health industries.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:32 pm

SPR

Spirit AeroSystems has issued a statement regarding Alaska Airlines Flight 1282, indicating that they are following the protocols set by regulatory authorities guiding communication.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:30 pm

AFMD

Affimed N.V. has reaffirmed its guidance for the release of data readouts for two of its clinical trials, AFM24-102 and LuminICE-203, which are expected in the first half of 2024. This confirmation may indicate progress in the company's clinical programs and could be a positive signal to investors looking forward to these milestones.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:29 pm

ADTX

Trading on ADTX has been halted at 8:25:00 a.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material news.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:25 pm

ABSI

Absci Corporation announced it will present preclinical data for its anti-TL1A antibody development program, ABS-101, at the 42nd Annual J.P. Morgan Healthcare Conference. The company expects to submit an Investigational New Drug (IND) application for ABS-101 in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:24 pm

ENSC

Ensysce Biosciences CEO Lynn Kirkpatrick released a 2024 shareholder letter detailing the company's progress in 2023, focusing on the development of their lead analgesic PF614 and PF614-MPAR, both designed to treat severe pain with overdose protection. The company presented clinical data at various scientific meetings, completed clinical trials, and prepared for regulatory submissions to the FDA. They also engaged Alacrita Consulting for business development and explored a partnership with OncoZenge AB for a non-opioid pain treatment. Ensysce raised $12 million in financing to support their clinical programs and is preparing for FDA discussions to advance PF614 and PF614-MPAR through the 505(B)(2) regulatory pathway.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:23 pm

BT

BT Group's tech incubation unit, Etc., plans to convert traditional broadband street cabinets into EV charging stations in the U.K. The first conversion will take place in East Lothian, Scotland, with technical trials across 60,000 cabinets to address the shortage of public EV charging points. The U.K. government aims to increase charging points to 300,000 by 2030, and BT Group's initiative could help overcome the infrastructure barrier deterring potential EV buyers. The project will assess technical, commercial, and operational factors and has been recognized with an Innovation Honoree award at CES for 2024.

Portfolio Pulse from Benzinga Neuro

January 08, 2024 | 1:22 pm

HARP

LMDX

SPR

LumiraDx Limited (NASDAQ:LMDX) shares plummeted over 30% in pre-market trading due to the announcement that its securities will be suspended from Nasdaq trading starting January 9th. Other stocks experienced significant movement in pre-market trading, with Harpoon Therapeutics, Inc. (NASDAQ:HARP) seeing a near 100% gain after reports of Merck's acquisition talks, and Spirit AeroSystems Holdings, Inc. (NYSE:SPR) dropping over 16% following the FAA's grounding of certain Boeing 737 Max 9 aircraft.

Portfolio Pulse from Avi Kapoor

January 08, 2024 | 1:20 pm

BAC

C

JPM

WFC

U.S. banking giants are facing a challenging fourth quarter with a rise in bad debts and the impact of higher interest rates. Non-performing loans at the four largest U.S. banks have increased by nearly $6 billion, reaching $24.4 billion. The banks are also expected to take a one-time charge due to a special assessment by the FDIC related to the failures of Silicon Valley Bank and Signature. Despite these challenges, bank shares have risen by 20% since October, buoyed by the Fed's signals of halting interest rate hikes. JPMorgan Chase & Co. (JPM), Bank of America Corp (BAC), Wells Fargo & Co (WFC), and Citigroup Inc. (C) are set to report earnings on Jan. 12.

Portfolio Pulse from Benzinga Neuro

January 08, 2024 | 1:17 pm